I'm not sure how to take this press release. On one hand it's great news that Frequency is garnering additional funding for their PCA technology, but on the other hand, the article states: "Research Award will support translational preclinical and early-stage clinical research to address hearing dysfunction resulting from military service-related injuries".
FX-322 is well past the preclinical and early-stage clinical research phase, which leads me to speculate whether or not there is some underlying biological shortcoming to this drug that requires further investigation, or is this a broader play for other vestibular disorders? The whole press release eludes to hearing loss specifically, so I'm kinda confused at what this funding aims to accomplish specifically.
Either way, I'm keeping the glass half full. Any funding and attention to these maladies is a win.